Primary Site >> Colorectal Cancer
Gene >> PLK1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Cell cycle molecular targets in novel anticancer drug discovery. PMID: 10788588 |
Ref: Comparative expression of the mitotic regulators SAK and PLK in colorectal cancer. PMID: 11597015 |
Ref: Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. PMID: 11743651 Ref: Gene expression differences between the microsatellite instability (MIN) and chromosomal instability (CIN) phenotypes in colorectal cancer revealed by high-density cDNA array hybridization. PMID: 12082642 Ref: Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. PMID: 12488480 |
Ref: Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. PMID: 12708489 |
Ref: p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. PMID: 15016801 |
Ref: Polo-like kinases (Plks) and cancer. PMID: 15640844 Ref: Apoptosis induction with polo-like kinase-1 antisense phosphorothioate oligodeoxynucleotide of colon cancer cell line SW480. PMID: 16052696 Ref: Polo-like kinase 1 expression is a prognostic factor in human colon cancer. PMID: 16237758 |
Ref: [Knockdown of PLK1 mRNA by special siRNA]. PMID: 16469711 Ref: Aberrant Wnt/beta-catenin signaling can induce chromosomal instability in colon cancer. PMID: 16815967 Ref: Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition. PMID: 16887021 Ref: A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. PMID: 16951237 Ref: Low dietary folate initiates intestinal tumors in mice, with altered expression of G2-M checkpoint regulators polo-like kinase 1 and cell division cycle 25c. PMID: 17079455 |
Ref: Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. PMID: 17615082 Ref: The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis. PMID: 18075315 |
Ref: The database dbEST correctly predicts gene expression in colon cancer patients. PMID: 19075689 |
Ref: Discovery and scoring of protein interaction subnetworks discriminative of late stage human colon cancer. PMID: 19098285 Ref: A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. PMID: 19225112 Ref: BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. PMID: 19383823 Ref: Nucleation capacity and presence of centrioles define a distinct category of centrosome abnormalities that induces multipolar mitoses in cancer cells. PMID: 19768832 |
Ref: Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. PMID: 20581060 |
Ref: A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. PMID: 20473941 Ref: [Influence of silencing Polo-like kinase 1 on migration and invasion of colorectal cancer cells]. PMID: 21271384 Ref: Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo. PMID: 21797676 |
Ref: Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population. PMID: 22001602 Ref: Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). PMID: 22070629 Ref: TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens. PMID: 22188812 Ref: p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors. PMID: 22262171 Ref: Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. PMID: 22648245 Ref: Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells. PMID: 22753241 Ref: Enhanced chemosensitivity to CPT-11 in colorectal carcinoma xenografts by small hairpin RNA interference targeting PLK1. PMID: 22862168 |
Ref: Identification of novel compounds that enhance colon cancer cell sensitivity to inflammatory apoptotic ligands. PMID: 23377828 Ref: Cell cycle-dependent localization of CHK2 at centrosomes during mitosis. PMID: 23680298 Ref: PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. PMID: 23887393 Ref: TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. PMID: 23909892 Ref: Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. PMID: 24159333 |
Ref: PLK1-inhibition can cause radiosensitization or radioresistance dependent on the treatment schedule. PMID: 24502970 Ref: Expression of the microtubule-associated protein MAP9/ASAP and its partners AURKA and PLK1 in colorectal and breast cancers. PMID: 24876664 |
Ref: GSK-3 modulates cellular responses to a broad spectrum of kinase inhibitors. PMID: 25402767 Ref: Upregulated Polo-Like Kinase 1 Expression Correlates with Inferior Survival Outcomes in Rectal Cancer. PMID: 26047016 |
Ref: PLK-1 Expression is Associated with Histopathological Response to Neoadjuvant Therapy of Hepatic Metastasis of Colorectal Carcinoma. PMID: 26577686 Ref: Study of apoptosis-related interactions in colorectal cancer. PMID: 27629291 Ref: Effect of AKT3 expression on MYC- and caspase-8-dependent apoptosis caused by polo-like kinase inhibitors in HCT 116 cells. PMID: 27699933 Ref: Decreased PLK1 expression denotes therapy resistance and unfavourable disease-free survival in rectal cancer patients receiving neoadjuvant chemoradiotherapy. PMID: 27712975 |
Ref: YPC-21661 and YPC-22026, novel small molecules, inhibit ZNF143 activity in vitro and in vivo. PMID: 28192620 Ref: Polo-like kinase 1 expression is suppressed by CCAAT/enhancer-binding protein alpha to mediate colon carcinoma cell differentiation and apoptosis. PMID: 28341486 Ref: Next-generation sequencing traces human induced pluripotent stem cell lines clonally generated from heterogeneous cancer tissue. PMID: 28596815 |
Ref: Simultaneous use of erythropoietin and LFM-A13 as a new therapeutic approach for colorectal cancer. PMID: 29160911 Ref: Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. PMID: 29402316 Ref: PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells. PMID: 29549256 Ref: G9a stimulates CRC growth by inducing p53 Lys373 dimethylation-dependent activation of Plk1. PMID: 29774081 |